Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAP (TGF-beta 1)

LAP (TGF-beta 1)

Brief Information

Name:Transforming growth factor beta 1
Target Synonym:Latency-Associated Peptide,IBDIMDE,Transforming Growth Factor beta1,Prepro-Transforming Growth Factor Beta-1,TGF-Beta-1,Transforming Growth Factor, Beta 1,CED,TGFB,DPD1,TGFB1,Transforming Growth Factor Beta-1 Proprotein,Camurati-Engelmann Disease,LAP,TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

Human LAP (TGF-beta 1), Tag FreeHuman LAP (TGF-beta 1), Tag Free (Cat. No. LAP-H5213) ELISA bioactivity

Immobilized Human LAP (TGF-beta 1), Tag Free (Cat. No. LAP-H5213) at 1 μg/mL (100 μL/well) can bind Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) with a linear range of 5-39 ng/mL (QC tested).

Biotinylated Human LAP (TGF-beta 1) (C33S), Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human LAP (TGF-beta 1) (C33S), Fc,Avitag (Cat. No. LAP-H82F8) is more than 90% and the molecular weight of this protein is around 129-157kDa verified by SEC-MALS.

Biotinylated Human LAP (TGF-beta 1) (C33S), Fc,AvitagBiotinylated Human LAP (TGF-beta 1) (C33S), Fc,Avitag (Cat. No. LAP-H82F8) ELISA bioactivity

Immobilized Human ITGAV&ITGB8 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT8-H52W4) at 5 μg/mL (100 μL/well) can bind Biotinylated Human LAP (TGF-beta 1), Fc,Avitag (Cat. No. LAP-H82F8) with a linear range of 0.2-6 ng/mL (QC tested).

Synonym Name



Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AVID-200 AVID-200; BMS-986416; AVID-200 DP Phase 1 Clinical Formation Biologics Corp Solid tumours; Neoplasms; Primary Myelofibrosis; Scleroderma, Diffuse Details
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
Cotsiranib STP-705LU; STP-705LV; STP-705; STP-705L Phase 2 Clinical Sirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Liver Neoplasms; Carcinoma, Basal Cell; Bowen's Disease; Cholangiocarcinoma; Carcinoma, Squamous Cell; Obesity, Abdominal; Keloid; Carcinoma, Hepatocellular; Cicatrix, Hypertrophic Details
Meflonidone hydrochloride Phase 1 Clinical Guangzhou Nanxin Pharma Co Ltd, Central South University Diabetic Nephropathies Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial Details
Dalutrafusp alfa AGEN-1423; GS-1423 Phase 2 Clinical Gilead Inc, Agenus Inc Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal Details
SRK-181 SRK-181 Phase 1 Clinical Scholar Rock Neoplasms Details
HRG-2101 HRG-2101 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Idiopathic Pulmonary Fibrosis Details
PXS-64 PXS-64 Phase 1 Clinical Pharmaxis Ltd Multiple Sclerosis Details
SB-01 (Spine Biopharma) SB-01 Phase 3 Clinical Spine BioPharma Inc Intervertebral disc disease; Low Back Pain Details
ZSP-1603 ZSP-1603 Phase 2 Clinical Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NNC-0361-0041 NNC0361-0041; NNC-0361-0041 Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1 Details
STP-707 STP-707 Phase 1 Clinical Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd Liver Neoplasms; Solid tumours; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing Details
Fluorofenidone AKF-PD Phase 2 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis Details
Livmoniplimab ABBV151; MGH-8; ARGX-115; AGRX-115 Phase 1 Clinical Argenx Se, Abbvie Inc Solid tumours Details
JYB-1907 JYB-1907 Phase 1 Clinical Jiangxi Jemincare Group Co Ltd Solid tumours Details
Charis-1000 Charis-1000; C 1K; C1K Phase 1 Clinical Ensol Biosciences Breast Neoplasms Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Gallbladder Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Sarcoma; Prostatic Neoplasms; Microsatellite Instability; Breast Neoplasms; Vulvar Neoplasms; Thymus Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Thymoma; Lung Neoplasms; Penile Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Sarcoma, Kaposi; Stomach Neoplasms; Biliary Tract Neoplasms; Intestinal Neoplasms; Head and Neck Neoplasms; Esthesioneuroblastoma, Olfactory; Carcinoma; Carcinoma, Renal Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Anus Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Ganglioglioma; Nose Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Carcinoma, Transitional Cell; Respiratory papillomatosis; Adenomyoepithelioma Details
YL-13027 YL-13027 Phase 2 Clinical YL-Pharma Solid tumours; Neoplasms Details
NIS-793(Novartis Pharma) NIS-793 Phase 3 Clinical Novartis Pharma Ag Liver Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma Details
Vactosertib EW-7197; NOV-1301; TEW-7197 Phase 2 Clinical Medpacto Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Myeloproliferative Disorders; Osteosarcoma; Colorectal Neoplasms; Urologic Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message